Literature DB >> 6280597

Single-dose pharmacokinetics of ceftriaxone in infants and young children.

U B Schaad, K Stoeckel.   

Abstract

The pharmacokinetics of ceftriaxone were studied in five infants (7 to 15 months old) and five young children (24 to 70 months old). Both groups received a single 50-mg/kg dose in an intravenous infusion over 5 min. No major pharmacokinetic differences were observed between the two populations. The total (bound plus unbound) plasma concentration-versus-time data could be described in each case by a biexponential equation. Changes in renal clearance indicated time- and dose- dependent pharmacokinetic behavior. The fraction excreted unchanged in the urine (fu) and the biological half-life (t 1/2 (beta)) were, however, dose independent. The average values were 47% for fu (0 to 12 h) and 6.5 for T 1/2 (beta). Weight-corrected total systemic clearance was C1TS = 0.71 ml/min per kg; volume of distribution was VD (beta) = 394 mg/kg. The data support intravenous administration of 50 mg of ceftriaxone per kg of body weight every 12 h in assessing its activity against Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis in postneonatal-stage pediatric patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6280597      PMCID: PMC181867          DOI: 10.1128/AAC.21.2.248

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Effect of ampicillin and chloramphenicol against Streptococcus pneumoniae and Neisseria meningitidis.

Authors:  W E Feldman; T Zweighaft
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

Review 2.  The current status of chloramphenicol.

Authors:  H C Meissner; A L Smith
Journal:  Pediatrics       Date:  1979-09       Impact factor: 7.124

3.  Increasing incidence of ampicillin resistance in Hemophilus influenzae.

Authors:  V Syriopoulou; D Scheifele; A L Smith; P M Perry; V Howie
Journal:  J Pediatr       Date:  1978-06       Impact factor: 4.406

4.  Cefotaxime in the treatment of severe paediatric infections.

Authors:  C J Papadatos; D A Kafetzis; J Kanarios
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  The increasing frequency of beta-lactamase-producing Haemophilus influenzae B.

Authors:  J D Nelson
Journal:  JAMA       Date:  1980-07-18       Impact factor: 56.272

6.  Meningitis due to Haemophilus influenzae type b resistant to ampicillin and chloramphenicol.

Authors:  N Uchiyama; G R Greene; D B Kitts; L D Thrupp
Journal:  J Pediatr       Date:  1980-09       Impact factor: 4.406

7.  Penicillin-insensitive pneumococci. Case report and review.

Authors:  G A Ahronheim; B Reich; M I Marks
Journal:  Am J Dis Child       Date:  1979-02

8.  In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.

Authors:  S Shelton; J D Nelson; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

9.  Meningitis due to Haemophilus influenzae type b resistant to both ampicillin and chloramphenicol.

Authors:  J F Kenny; C D Isburg; R H Michaels
Journal:  Pediatrics       Date:  1980-07       Impact factor: 7.124

10.  Chloramphenicol pharmacokinetics in infants and young children.

Authors:  C M Sack; J R Koup; A L Smith
Journal:  Pediatrics       Date:  1980-10       Impact factor: 7.124

View more
  32 in total

1.  Intravenous Push Administration of Antibiotics: Literature and Considerations.

Authors:  Samantha Spencer; Heather Ipema; Patricia Hartke; Courtney Krueger; Ryan Rodriguez; Alan E Gross; Michael Gabay
Journal:  Hosp Pharm       Date:  2018-03-08

2.  Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci.

Authors:  K S Kim; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

3.  Disulfiram-like Reaction Involving Ceftriaxone in a Pediatric Patient.

Authors:  Stephen M Small; Rachel S Bacher; Sheridan A Jost
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 4.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Evaluation of a potential clinical interaction between ceftriaxone and calcium.

Authors:  Emily Steadman; Dennis W Raisch; Charles L Bennett; John S Esterly; Tischa Becker; Michael Postelnick; June M McKoy; Steve Trifilio; Paul R Yarnold; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 6.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

7.  Comparison of ceftriaxone and traditional therapy of bacterial meningitis.

Authors:  B L Congeni
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 8.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

9.  Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis.

Authors:  R Latif; A S Dajani
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

10.  Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial.

Authors:  A Islam; T Butler; I Kabir; N H Alam
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.